A - Human Necessities – 61 – B
Patent
A - Human Necessities
61
B
A61B 5/026 (2006.01) A61B 5/00 (2006.01) A61B 5/145 (2006.01) A61B 8/06 (2006.01) A61M 37/00 (2006.01) G01N 33/15 (2006.01)
Patent
CA 2512060
A method for determining and demonstrating the role of vasodilator chemical agents in the development and practice of transdermal drug delivery systems. Vasodilator chemicals applied topically dilate the blood vessels in the skin tissue, which have been shown to facilitate or inhibit systemic or skin tissue deposition of drug substances. The level of stimulation and/or inhibition has been found to be dependent on the concentration and the identity of the specific vasodilator chemical(s) used as well as the drug molecule(s) to be delivered. This work teaches the need to consider specific formulation requirements when dealing with vasodilator chemicals for the creation of successful delivery vehicles in the transdermal drug delivery system. These requirements for very low concentrations of vasodilators were an unexpected and a surprise finding, in contrast to the concentrations of the vasodilators typically used to elicit an increase in skin blood flow.
Carter Stephen G.
Patel Kanu
Zhu Zhen
Biochemics Inc.
Deeth Williams Wall Llp
LandOfFree
Transdermal drug delivery formulations and method of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Transdermal drug delivery formulations and method of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Transdermal drug delivery formulations and method of... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1949311